Literature DB >> 32783656

A hypertension patient-derived iPSC model demonstrates a role for G protein-coupled estrogen receptor in hypertension risk and development.

Natalie C Fredette1, Eliyah Malik1, Marah L Mukhtar2, Eric R Prossnitz3, Naohiro Terada1.   

Abstract

Hypertension (HTN) is a polyfactorial disease that can manifest severe cardiovascular pathologies such as heart failure or stroke. Genome-wide association studies (GWAS) of HTN indicate that single-nucleotide polymorphisms (SNPs) contribute to increased risk for HTN and resistance to some HTN drug regimens (Hiltunen TP et al., J Am Heart Assoc 4: e001521, 2015; Le MT et al., PLoS One 8: e52062, 2013; McDonough CW et al., J Hypertens 31: 698-704, 2013; Vandell AG et al., Hypertension 60: 957-964, 2012). However, cellular mechanistic insights of such SNPs remain largely unknown. Using a bank of induced pluripotent stem cells (iPSCs) derived from patients with HTN and CRISPR/Cas9-mediated gene-editing approach, we investigated the effects of a female HTN risk-associated SNP (rs1154431) of the G protein-coupled estrogen receptor (GPER) (Bassuk SS, Manson JE., Clin Chem 60: 68-77, 2014) in vascular endothelial cells. Although GPER1 deletion reduced endothelial nitric oxide synthase (eNOS) activation in iPSC-derived endothelial cells (iECs), the polymorphism itself did not significantly affect eNOS and NO production in a comparison of isogenic hemizygous iECs expressing either normal (P16) or HTN-associated (L16) GPER. Interestingly, we demonstrate for the first time that GPER plays a role in regulation of adhesion molecule expression and monocyte adhesion to iECs. Moreover, the L16 iECs had higher expression of inflammation genes than P16 iECs, implying that the risk variant may affect carrier individuals through increased inflammatory activity. This study further indicates that iPSCs are a useful platform for exploring mechanistic insights underlying hypertension GWAS endeavors.

Entities:  

Keywords:  GPER; endothelial; hypertension; iPSC; single-nucleotide polymorphism

Mesh:

Substances:

Year:  2020        PMID: 32783656      PMCID: PMC7701270          DOI: 10.1152/ajpcell.00350.2019

Source DB:  PubMed          Journal:  Am J Physiol Cell Physiol        ISSN: 0363-6143            Impact factor:   4.249


  54 in total

1.  GPER Agonist G1 Attenuates Neuroinflammation and Dopaminergic Neurodegeneration in Parkinson Disease.

Authors:  Jing Guan; Beibei Yang; Yi Fan; Ji Zhang
Journal:  Neuroimmunomodulation       Date:  2017-08-16       Impact factor: 2.492

Review 2.  Sex Hormones and Cardiometabolic Health: Role of Estrogen and Estrogen Receptors.

Authors:  Deborah Clegg; Andrea L Hevener; Kerrie L Moreau; Eugenia Morselli; Alfredo Criollo; Rachael E Van Pelt; Victoria J Vieira-Potter
Journal:  Endocrinology       Date:  2017-05-01       Impact factor: 4.736

3.  Estrogen receptor GPR30 reduces oxidative stress and proteinuria in the salt-sensitive female mRen2.Lewis rat.

Authors:  Sarah H Lindsey; Liliya M Yamaleyeva; K Bridget Brosnihan; Patricia E Gallagher; Mark C Chappell
Journal:  Hypertension       Date:  2011-08-15       Impact factor: 10.190

Review 4.  "Gender specific medicine": a focus on gender-differences in hypertension.

Authors:  H Bălan; Livia Popescu
Journal:  Rom J Intern Med       Date:  2014

5.  Estrogen, vascular estrogen receptor and hormone therapy in postmenopausal vascular disease.

Authors:  Raouf A Khalil
Journal:  Biochem Pharmacol       Date:  2013-10-04       Impact factor: 5.858

6.  Implications of the Eighth Joint National Committee Guidelines for the Management of High Blood Pressure for Aging Adults: Atherosclerosis Risk in Communities Study.

Authors:  Michael D Miedema; Faye L Lopez; Michael J Blaha; Salim S Virani; Josef Coresh; Christie M Ballantyne; Aaron R Folsom
Journal:  Hypertension       Date:  2015-07-06       Impact factor: 10.190

7.  Pharmacogenomics of antihypertensive drugs: rationale and design of the Pharmacogenomic Evaluation of Antihypertensive Responses (PEAR) study.

Authors:  Julie A Johnson; Eric Boerwinkle; Issam Zineh; Arlene B Chapman; Kent Bailey; Rhonda M Cooper-DeHoff; John Gums; R Whit Curry; Yan Gong; Amber L Beitelshees; Gary Schwartz; Stephen T Turner
Journal:  Am Heart J       Date:  2009-03       Impact factor: 4.749

Review 8.  Membrane-initiated actions of estrogen on the endothelium.

Authors:  Kyung Hee Kim; Jeffrey R Bender
Journal:  Mol Cell Endocrinol       Date:  2009-04-09       Impact factor: 4.102

9.  Impact of genetic polymorphisms of SLC2A2, SLC2A5, and KHK on metabolic phenotypes in hypertensive individuals.

Authors:  MyPhuong T Le; Maximilian T Lobmeyer; Marcus Campbell; Jing Cheng; Zhiying Wang; Stephen T Turner; Arlene B Chapman; Eric Boerwinkle; John G Gums; Yan Gong; Richard J Johnson; Julie A Johnson
Journal:  PLoS One       Date:  2013-01-14       Impact factor: 3.240

Review 10.  Heart Disease in Women: Unappreciated Challenges, GPER as a New Target.

Authors:  Ross D Feldman
Journal:  Int J Mol Sci       Date:  2016-05-18       Impact factor: 5.923

View more
  3 in total

Review 1.  Deciphering pathogenicity of variants of uncertain significance with CRISPR-edited iPSCs.

Authors:  Hongchao Guo; Lichao Liu; Masataka Nishiga; Le Cong; Joseph C Wu
Journal:  Trends Genet       Date:  2021-09-08       Impact factor: 11.639

Review 2.  Estrogen Receptors: Therapeutic Perspectives for the Treatment of Cardiac Dysfunction after Myocardial Infarction.

Authors:  Jaqueline S da Silva; Tadeu L Montagnoli; Bruna S Rocha; Matheus L C A Tacco; Sophia C P Marinho; Gisele Zapata-Sudo
Journal:  Int J Mol Sci       Date:  2021-01-07       Impact factor: 5.923

3.  Use of Induced Pluripotent Stem Cells to Build Isogenic Systems and Investigate Type 1 Diabetes.

Authors:  Lucas H Armitage; Scott E Stimpson; Katherine E Santostefano; Lina Sui; Similoluwa Ogundare; Brittney N Newby; Roberto Castro-Gutierrez; Mollie K Huber; Jared P Taylor; Prerana Sharma; Ilian A Radichev; Daniel J Perry; Natalie C Fredette; Alexei Y Savinov; Mark A Wallet; Naohiro Terada; Todd M Brusko; Holger A Russ; Jing Chen; Dieter Egli; Clayton E Mathews
Journal:  Front Endocrinol (Lausanne)       Date:  2021-11-09       Impact factor: 6.055

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.